Navigation Links
Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia
Date:12/8/2009

proprietary BiTE® antibody platform, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. Micromet's collaboration partners include sanofi-aventis, Bayer Schering Pharma, Nycomed, Merck Serono, and MedImmune.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of blinatumomab, the mode of action of BiTE antibodies, and the conduct, timing and results of future clinical trials of blinatumomab. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Par Pharmaceutical Receives Final Approval to Market Generic Ultram(R) ER
2. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
3. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
4. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
5. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
6. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
7. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
8. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
9. QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
10. White Paper Explains Aspects of Testing From Purified Bulk Drug Substance to Sterile Liquid Final Drug Product
11. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  CAS Medical Systems, Inc. (NASDAQ: CASM ... monitoring, today announced that Thomas M. Patton ... 2 nd Annual Marcum MicroCap Conference on Thursday, May ... New York City . The presentation is ... 10 room and will be available via a live webcast ...
(Date:5/23/2013)... -- Omeros Corporation (NASDAQ: OMER ) today ... to evaluate OMS824 in Huntington,s disease has been ... (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an ... to a wide range of diseases that affect ... shown promising results in animal models directly relevant ...
(Date:5/23/2013)...  Echo Pharma Acquisition Limited ("Royalty Pharma") announced today ... Threshold from 90 percent to 50 percent of Maximum ... with the terms of the Revised Offer Document issued ... Under the terms of the Increased Offer, Royalty Pharma ... ) for $12.50 per share in cash. The Increased ...
Breaking Medicine Technology:CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10
... Shands Jacksonville Medical Center ... (NASDAQ: MASI ) today jointly announce the ... SET Pulse CO-Oximetry™ technology for advanced noninvasive patient monitoring ... also operates one of the biggest and busiest trauma ...
... 2011 The Medical Oncology Association of Southern ... signed an agreement to work together to expand ... and costs of cancer care in Southern California. ... reimbursement and distribution services to help health care ...
Cached Medicine Technology:Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities 2Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities 3Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities 4Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities 5Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities 6Medical Oncology Association of Southern California, Cardinal Health Specialty Solutions Collaborate With Payors to Improve Quality, Costs, Accessibility of Cancer Care 2Medical Oncology Association of Southern California, Cardinal Health Specialty Solutions Collaborate With Payors to Improve Quality, Costs, Accessibility of Cancer Care 3
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 ... outreach program being tackled by the Safe Passage Committee ... Fullpower personal safety workshop for women on ... teaches personal safety skills programs for people of all ... us their experiences with street harassment for years,” said ...
(Date:5/23/2013)... May 23, 2013 Dimensional Insight, ... solutions, announced today that Paul Comras, director ... speak at the 2013 International Medical Users Software ... Expense & Revenue Visibility from Your General Ledger.” ... 29 from 2:30-3:25 p.m. in Azalea 1 at ...
(Date:5/23/2013)... IN (PRWEB) May 23, 2013 ... Modernfold, a DORMA company, is pleased to announce ... vinyl coverings for its pacesetting space division products. ... products and wallcoverings, the new patterns and colors ... , Through meetings with a team of ...
(Date:5/23/2013)... members of the PETA International Science Consortium, Ltd., ... Safety Improvement Act of 2013: , Reform of ... also modernizes toxicity testing. , Ensuring the ... important goal. Reforming the EPA,s Toxic Substances ... the National Research Council,s vision for transforming toxicity ...
(Date:5/23/2013)... Bronson Gray HealthDay Reporter , , WEDNESDAY, May 22 ... device used to save an infant born with a serious ... marriage of bioengineering and surgery. A report in the ... the situation that sparked the innovation. At first, the ... began to have difficulty breathing and eating when he was ...
Breaking Medicine News(10 mins):Health News:San Francisco Tenderloin Women Say “No!” to Street Harassment: Safe Passage Sponsors Kidpower Adult Safety Skills Workshops and Resources 2Health News:San Francisco Tenderloin Women Say “No!” to Street Harassment: Safe Passage Sponsors Kidpower Adult Safety Skills Workshops and Resources 3Health News:San Francisco Tenderloin Women Say “No!” to Street Harassment: Safe Passage Sponsors Kidpower Adult Safety Skills Workshops and Resources 4Health News:Dimensional Insight to Demonstrate How Hospitals Can Use Business Intelligence within MEDITECH Environments at 2013 International MUSE Conference 2Health News:Modernfold Debuts New Colors and Patterns for Space Division Products 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 3
... User,s ... HealthVault Profile, ANN ... delivers a variety of integrated healthcare services,announced that it has ... consumers collect, store, and share,health information online. The UNIVAL application, ...
... clinical nutritionist and women,s health practitioner, has formulated ... protection for beautiful skin, a strong immune system, ... vision. Dr. Lark,s Thrive! is available exclusively ... Healthy Directions, LLC, one of the largest North ...
... Every year in Jacksonville,nearly 600 adults experience ... long road to recovery lacked long-term support. Today, ... only program,in Florida created to help people with ... reintegration., The Brain Injury Association of America ...
... MADISON, N.J., Oct. 22 Wyeth (NYSE: WYE ),announced ... Ann Stribling v. Wyeth,in New Jersey State Court in ... assessed total damages of $3 million. Wyeth is reviewing,its ... finding and believe it is,unsupported by the evidence, which ...
... Utilizing a new, innovative,twist on the popular Christmas toy ... Points by Sheraton Denver Southeast and give,back to the ... and the community may donate new costumes for the,Kunsberg ... Jewish,Medical and Research Center., "The Glendale Raptors are ...
... how cancer develops , , WEDNESDAY, Oct. 22 (HealthDay News) -- ... have grown entire prostates in mice. , This feat was ... stem cells from other types of cells, according to a ... , This information still has to be confirmed in humans, ...
Cached Medicine News:Health News:UNIVAL(R), Inc. Becomes a Microsoft(R) HealthVault(TM) Application Provider 2Health News:Susan Lark, MD Develops a Powerful ORAC Drink Packed with the Antioxidant Power of Nine Fruits 2Health News:Susan Lark, MD Develops a Powerful ORAC Drink Packed with the Antioxidant Power of Nine Fruits 3Health News:Susan Lark, MD Develops a Powerful ORAC Drink Packed with the Antioxidant Power of Nine Fruits 4Health News:Brooks Rehabilitation Opens First Work-Based Brain Injury Rehab Program in Florida 2Health News:Glendale Raptors Join Four Points by Sheraton Denver Southeast and Animal Planet's Dr. Kevin Fitzgerald for Second Annual Halloween Costume Drive & Halloween Party for Kunsberg School at National Jewish Medical and Research Center 2Health News:New Prostrates Grown From Single Stem Cell 2
Straight 8 mm downcutting Royce blade. Can be placed in closed handle for protection. Rigid handle when folded and locked. Straight 8 mm downcutting blades. Handle length folded 109 mm, 4.3 inches....
Duckbill. 3.5 mm tip. Light curve....
2 mm. Angled 13 degrees, 15 mm from angle to tip. Round handle....
2 mm curved tip. Round handle. Designated most popular model or size....
Medicine Products: